Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

This study aimed to provide real-world evidence on progression risk in patients with high-risk smoldering multiple myeloma (SMM). This retrospective, observational study leveraged data from the Flatiron Health database. Eligible patients had SMM and relevant measures to apply Mayo 2018, Internationa...

Descripción completa

Detalles Bibliográficos
Autores: Rajkumar, S. Vincent, Mateos, Maria Victoria, Schaeffer, Marcy, Lin, Xiwu, Bathija, Sacheeta, Gupta-Werner, Niodita, Lam, Annette, Carson, Robin, Dennis, Robyn, Kaila, Shuchita, Matt, Kathryn, Duran, Joana, Lonial, Sagar
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/381693
Acceso en línea:http://hdl.handle.net/10261/381693
Access Level:acceso abierto
Palabra clave:Myeloma
Risk factors
id ES_7f077e7dbc2ff77eca09cfbfcb904249
oai_identifier_str oai:digital.csic.es:10261/381693
network_acronym_str ES
network_name_str España
repository_id_str
spelling Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health databaseRajkumar, S. VincentMateos, Maria VictoriaSchaeffer, MarcyLin, XiwuBathija, SacheetaGupta-Werner, NioditaLam, AnnetteCarson, RobinDennis, RobynKaila, ShuchitaMatt, KathrynDuran, JoanaLonial, SagarMyelomaRisk factorsThis study aimed to provide real-world evidence on progression risk in patients with high-risk smoldering multiple myeloma (SMM). This retrospective, observational study leveraged data from the Flatiron Health database. Eligible patients had SMM and relevant measures to apply Mayo 2018, International Myeloma Working Group (IMWG) 2020, and AQUILA trial risk criteria. Time to progression to active MM (TTP), progression or death (PFS), and death or progression on first-line MM therapy (PFS2) were evaluated using Kaplan–Meier methods and multivariate Cox regression models adjusted for age, Charlson Comorbidity Index, and time from SMM diagnosis to risk classification date. Across the three risk models (Mayo 2018, IMWG 2020, and AQUILA trial), high-risk patients with SMM had 3.0–4.0 times the risk of TTP, 2.1–3.5 times the risk of PFS, and 1.7–3.2 times the risk of PFS2 versus non-high-risk patients (p < 0.001 for all comparisons). Similar results were observed when patients with early treatment, early progression, and/or bone disease were excluded. This study demonstrates that high-risk patients with SMM have worse prognoses than non-high-risk patients, regardless of the criteria used, and highlights a need for early intervention testing.This study was funded by Janssen Research & Development, LLC. Medical writing support was provided by Kalika Mathur, PhD, on behalf of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC.Peer reviewedSpringer NatureJanssen Research and DevelopmentConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/381693reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésThe underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.1038/s41408-024-01170-zhttps://doi.org/10.1038/s41408-024-01170-zSíinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3816932026-05-22T06:33:51Z
dc.title.none.fl_str_mv Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
title Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
spellingShingle Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
Rajkumar, S. Vincent
Myeloma
Risk factors
title_short Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
title_full Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
title_fullStr Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
title_full_unstemmed Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
title_sort Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
dc.creator.none.fl_str_mv Rajkumar, S. Vincent
Mateos, Maria Victoria
Schaeffer, Marcy
Lin, Xiwu
Bathija, Sacheeta
Gupta-Werner, Niodita
Lam, Annette
Carson, Robin
Dennis, Robyn
Kaila, Shuchita
Matt, Kathryn
Duran, Joana
Lonial, Sagar
author Rajkumar, S. Vincent
author_facet Rajkumar, S. Vincent
Mateos, Maria Victoria
Schaeffer, Marcy
Lin, Xiwu
Bathija, Sacheeta
Gupta-Werner, Niodita
Lam, Annette
Carson, Robin
Dennis, Robyn
Kaila, Shuchita
Matt, Kathryn
Duran, Joana
Lonial, Sagar
author_role author
author2 Mateos, Maria Victoria
Schaeffer, Marcy
Lin, Xiwu
Bathija, Sacheeta
Gupta-Werner, Niodita
Lam, Annette
Carson, Robin
Dennis, Robyn
Kaila, Shuchita
Matt, Kathryn
Duran, Joana
Lonial, Sagar
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Janssen Research and Development
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Myeloma
Risk factors
topic Myeloma
Risk factors
description This study aimed to provide real-world evidence on progression risk in patients with high-risk smoldering multiple myeloma (SMM). This retrospective, observational study leveraged data from the Flatiron Health database. Eligible patients had SMM and relevant measures to apply Mayo 2018, International Myeloma Working Group (IMWG) 2020, and AQUILA trial risk criteria. Time to progression to active MM (TTP), progression or death (PFS), and death or progression on first-line MM therapy (PFS2) were evaluated using Kaplan–Meier methods and multivariate Cox regression models adjusted for age, Charlson Comorbidity Index, and time from SMM diagnosis to risk classification date. Across the three risk models (Mayo 2018, IMWG 2020, and AQUILA trial), high-risk patients with SMM had 3.0–4.0 times the risk of TTP, 2.1–3.5 times the risk of PFS, and 1.7–3.2 times the risk of PFS2 versus non-high-risk patients (p < 0.001 for all comparisons). Similar results were observed when patients with early treatment, early progression, and/or bone disease were excluded. This study demonstrates that high-risk patients with SMM have worse prognoses than non-high-risk patients, regardless of the criteria used, and highlights a need for early intervention testing.
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/381693
url http://hdl.handle.net/10261/381693
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.1038/s41408-024-01170-z
https://doi.org/10.1038/s41408-024-01170-z
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411793847189504
score 15.811543

Similares en LA Referencia